AI CuratorAI-generated

Research summary · 4 h ago

AI summary · not yet reviewedSubjects not reportedNot reportedPublished in a peer-reviewed journal

Survey of Neurologists on Diagnostic Tool Availability for MS

A survey conducted with 328 neurologists from 44 countries found that core diagnostic tools for multiple sclerosis (MS), like MRI and oligoclonal band testing, are generally accessible. However, the availability of advanced imaging, optic nerve assessments, and laboratory biomarkers differs significantly by region.

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42925001)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Human efficacy: Not established from this source
Mechanism: Not reported
Evidence strength: Not graded
Outcome: Not reported

Why it matters

Understanding the availability of diagnostic tools is crucial for consistent application of the 2024 McDonald criteria for MS diagnosis worldwide. Variability in access may hinder effective diagnosis and treatment across different regions.

What this does not prove

Variability in access to key paraclinical tests may impact on the implementation of the 2024 McDonald criteria globally.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Not reported
Participants / samples: Not reported
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: 2026-10-23
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified
Biological target: Not reported
Pathway: Not reported
Population: Not reported
Size of effect: Not reported
Secondary endpoints: Not reported
MRI endpoints: Not reported
Biomarkers: Not reported
Safety: Not reported

Original sources

Primary evidenceAvailability of resources to apply the 2024 McDonald criteria: A global perspective. ↗DOI: 10.1177/13524585261493315

Supporting passages (4)

publication datePublication date: 2026-10-23

limitationsCONCLUSIONS: Variability in access to key paraclinical tests may impact on the implementation of the 2024 McDonald criteria globally.

findingsRESULTS: The survey was completed by 328 neurologists from 44 countries. Core diagnostic tools, including magnetic resonance imaging and oligoclonal band testing, were widely available. Access to advanced imaging, optic nerve assessment, and laboratory biomarkers varied across regions.

peer reviewedPublication types: Journal Article

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.